ArticleIrish journal of medical science2026
Real-world antipsychotic prescribing patterns in psychotic disorders: polypharmacy, clozapine, and long-acting injectable use in a tertiary outpatient cohort.
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntipsychotic polypharmacy (APP) remains common in schizophrenia despite guideline recommendations favoring monotherapy. Real-world prescribing patterns involving clozapine and long-acting injectable (LAI) antipsychotics may offer insights into treatment complexity in tertiary psychiatric settings.
methodsThis retrospective cross-sectional study included 114 outpatients with schizophrenia or schizoaffective disorder attending a tertiary psychotic disorders unit in Türkiye between June and November 2021. Sociodemographic and clinical variables were obtained from routine records. Symptom severity and functioning were assessed using the Brief Psychiatric Rating Scale, Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia, and Global Assessment of Functioning. Patients were evaluated by APP status, clozapine use, and LAI use. Logistic regression analyses identified factors associated with APP and clozapine treatment.
resultsOverall, 65.7% received antipsychotic monotherapy, while 32.4% received two or more agents. Aripiprazole (30.7%), olanzapine (28.1%), and clozapine (25.4%) were most frequently prescribed, with aripiprazole the most common in APP regimens. LAIs were prescribed in 18.4% of patients. APP was associated with longer illness duration and lower employment rates. Clozapine use was independently associated with longer illness duration and higher PANSS negative symptom scores.
conclusionsAPP remains common in tertiary outpatient psychotic disorders care and may reflect treatment complexity beyond illness severity, underscoring individualized prescribing strategies. Clozapine use is associated with longer illness duration and greater negative symptom burden, although delays in initiation may persist. Prospective studies are needed to clarify optimal strategies and improve individualized care.
Indexed as
Identifiers
42400806What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.